Form Bio Announces New Scientific Advisory Board to Enhance AI-Driven Cell and Gene Therapy Development

Form Bio, a key player in computational life sciences, has declared the establishment of a new Scientific Advisory Board (SAB) as of April 18, 2024, in Dallas, Texas. The board, enriched with top experts from both industry and academia, is anticipated to steer the company’s R&D in life sciences, especially aiming to enhance therapeutic developments and clinical outcomes in biotech and pharma sectors through AI technologies.

The experts on the board encompass leaders like Steven Gray, Noriyuki Kasahara, Chengwen Li, Paris Margaritis, and Dolan Sondhi, contributing a vast range of expertise from vector engineering to gene therapy optimization. This strategic move underlines Form Bio’s commitment to accelerating the development of cell and gene therapies using AI, fundamentally from design to IND submission, thus aiming to reduce development timelines and improve efficacy in treatments.

Among other roles, the SAB will offer advanced strategies and expertise crucial for furthering Form Bio’s mission in the AI era of cellular and genetic therapy. It is a step towards optimizing the construct design processes and achieving better safety, efficiency, and market readiness. The advisory board’s collective knowledge is expected to populate new modalities for treating debilitating diseases, echoing through Form Bio’s future in silico programs.